Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

• by Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren

• May 17, 2026

Mental Health May Impact Dermatologic Quality of Life

Poorer dermatology-related quality of life was associated with greater mental health issues, while habitual probiotic intake showed no measurable relationship with these outcomes.

• by Andrea Surnit

• July 9, 2026

• 3 min

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

• by Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G. Bunick, Vishvas Garg, Emanuele Leoncini, Blair Kaplan, Richard Ta, Bang Truong, Dolly Sharma, Bruce Strober

• July 2, 2026

GRAPPA, EULAR Criteria May Identify Complex PsA

Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.

• by Andrea Surnit

• July 23, 2026

• 3 min